Clinical Trial Update: Quetiapine Extended Release Depression Symptoms [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating quetiapine extended-release for schizophrenia and depressive symptoms has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Schizophrenia

Drugs mentioned

• SEROQUEL XR (Quetiapine)

Snippet

Sponsor: AstraZeneca | Conditions: Schizophrenia, Depression | Phase 3 | Status: COMPLETED | Results posted: 2012-06-19